Because pancreatic cancer itself is an immune desert, there is an extreme lack of tumor specific effector T cell infiltration.[17] Therefore, we established a novel combination immunotherapy strategy here, that is, antibodies targeting MSLN combined with personalized neoantigen vaccines. This evidence concerns the gene MSLN and familial pancreatic carcinoma.